Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Assets: 2017-2025

Historic Current Assets for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $882.6 million.

  • Denali Therapeutics' Current Assets rose 1.58% to $882.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $882.6 million, marking a year-over-year increase of 1.58%. This contributed to the annual value of $864.4 million for FY2024, which is 18.77% down from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Current Assets is $882.6 million, which was down 5.57% from $934.7 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Current Assets peaked at $1.4 billion during Q1 2021, and registered a low of $864.4 million during Q4 2024.
  • Its 3-year average for Current Assets is $1.0 billion, with a median of $934.7 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Denali Therapeutics' Current Assets was 139.85% (2021), while the steepest drop was 40.01% (2021).
  • Denali Therapeutics' Current Assets (Quarterly) stood at $897.2 million in 2021, then surged by 52.95% to $1.4 billion in 2022, then declined by 22.46% to $1.1 billion in 2023, then fell by 18.77% to $864.4 million in 2024, then climbed by 1.58% to $882.6 million in 2025.
  • Its Current Assets stands at $882.6 million for Q3 2025, versus $934.7 million for Q2 2025 and $878.6 million for Q1 2025.